Ezetimibe inhibe la adhesión y la migración de monocitos a través de la ruta de las proteincinasas activadas extracelularmente (p44/p42ERK1/2

Our results indicate that, in addition to its lipid lowering activity, ezetimibe is able to inhibit the process of adhesion and migration of monocytes in vitro. Blocking of the p44/p42ERK1/2 MAPK signalling pathway seems to play a role in this anti-inflammatory effect.